Professional
Added to YB: 2025-10-15
Pitch date: 2025-10-06
AVXL [bearish]
Anavex Life Sciences Corp.
+6.68%
current return
Author Info
No bio for this author
Company Info
Anavex Life Sciences Corp. operates as a biopharmaceutical company. It engages in the development of novel therapeutics for the treatment of neurodegenerative, neurodevelopmental, and neuropsychiatric disorders, including Alzheimer's disease, Parkinson's disease, schizophrenia, Rett syndrome, and other central nervous system (CNS) diseases, pain, and various types of cancer.
Market Cap
$796.2M
Pitch Price
$9.65
Price Target
2.37 (-74%)
Dividend
N/A
EV/EBITDA
N/A
P/E
-16.36
EV/Sales
N/A
Sector
Biotechnology
Category
special_situation
Anavex Life Sciences: Dizzying Expectations of a Drug That Doesn’t Work
AVXL short: Pre-commercial biotech targeting EU approval for blarcamesine AD drug. Phase III failed 1/2 co-primary endpoints; successful endpoint showed efficacy only at week 48. Serious AEs: 36% dizziness vs 6% placebo, 14% confusion vs 0.6%. CHMP LoOI sent Sept; decision expected Nov-Dec. Price target $2-5 on rejection vs current $10+.
Read full article (19 min)